|
|
FDADocs 5/9/2008 | 0 (0) | 44 | 0 | 0 | English
_`°"
DEPA RTME N T OF HEALTH AND HUMAN SERVICES
Public Health Service 5100 Paint Branch Parkway Food and Drug Administration College Park, Maryland 20740
MAR 2 9 2006
Irene Gomez, :Regulatory Consultant FDA Experts 3509 W. Beverly Blvd., Montebello, California 90640
Dear Ms Gomez : This is to inform you that the notification, dated August 17, 2 ... more>>
FDADocs 5/9/2008 | 0 (0) | 76 | 0 | 0 | English
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Division of Dermatologic and Dental Drug Products Office of Drug Evaluation V Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD 20878 Tel FAX 301-827-2020 301-827-2075
M E M O R A N D U M
Date: From: Through: To: Cc: October 11, 2005 Markham C. Luke, M. ... more>>
FDADocs 5/12/2008 | 0 (0) | 27 | 1 | 0 | English
FDADocs 5/9/2008 | 0 (0) | 17 | 0 | 0 | English
CONTENTS
Exhibit 1 FDA March 1, 2004 letter from Gary J. Buehler, Director, Office of Generic Drugs, Center for Drug Evaluation.,and; Resepyh $o A@D$I $$plicants for / _” “. Metaxalone Tablets Declaration of Dr. Paul Bass, Professor Emeritus of Pharmacology at the University of W isconsin -- Madison Morey, “Metaxalone, a New Skeletal Muscle Relaxan ... more>>
FDADocs 5/9/2008 | 0 (0) | 47 | 0 | 0 | English
FDADocs 5/9/2008 | 0 (0) | 27 | 1 | 0 | English
NDA 20-717/S-019
November 2005
SPARLON™ (modafinil) Tablets [C-IV]
Rx Only
DESCRIPTION SPARLON (modafinil) is an orally administered agent for the treatment of AttentionDeficit/Hyperactivity Disorder (ADHD). Modafinil was initially developed and is also marketed as a wakefulness-promoting agent PROVIGIL® Tablets. Modafinil is a racemic compound ... more>>
FDADocs 5/9/2008 | 0 (0) | 37 | 0 | 0 | English
FDA Executive Summary (Version 2) Prepared for the March 27, 2006, meeting of the Obstetrics & Gynecology Devices Panel P050011 Innovata plc ® Adept Adhesion Reduction Solution (4% Icodextrin Solution)
1.) INDICATIONS FOR USE
Adept Adhesion Reduction Solution (4% Icodextrin Solution) (Adept®) is intended for use as an adjunct to good surgical techn ... more>>
GovernmentDocs 5/5/2008 | 0 (0) | 52 | 0 | 0 | English
Draft Guidance for Industry and FDA Staff Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses
DRAFT GUIDANCE
This guidance document is being distr.ibutedfor comment purposes only. Document issued on: [release date of FR Notice]
Comments and suggestions r ... more>>
FDADocs 5/9/2008 | 0 (0) | 38 | 0 | 0 | English
FDA Executive Summary Prepared for the November 9, 2006 Dental Products Panel Company: Device: Document No.: Date: Medtronic Sofamor Danek InFuse® Bone Graft P050053 October 4, 2006
InFuse® Bone Graft is a combination product consisting of a device and a biologic drug. FDA has determined that InFuse® will be reviewed as a PMA device/drug with cons ... more>>
FDADocs 5/9/2008 | 0 (0) | 175 | 1 | 0 | English
FDADocs 5/9/2008 | 0 (0) | 34 | 0 | 0 | English
Heparin, Adverse Reactions – FDA’s Role
Main heparin update page: www.fda.gov/cder/drug/infopage/heparin/default.htm As of March 14, 2008
1
2
3
4
ADVERSE REACTION
Some patients experience severe allergic reaction/low blood pressure after receiving heparin.
REPORTING
A small percentage of adverse reactions are reported to Centers for Disease ... more>>
FDADocs 5/9/2008 | 0 (0) | 16 | 0 | 0 | English
FDADocs 5/6/2008 | 0 (0) | 59 | 0 | 0 | English
FDADocs 5/9/2008 | 0 (0) | 41 | 0 | 0 | English
Heparin, Import Alert – FDA’s Role
Main heparin update page: www.fda.gov/cder/drug/infopage/heparin/default.htm As of March 14, 2008
1
2
3
4
PRODUCT ENTRY
Heparin, including Active Pharmaceutical Ingredient (API) and finished heparin, enter U.S. ports from overseas.
IMPORT ALERT
FDA issues import alert on shipments from specified manufactur ... more>>
FDADocs 5/12/2008 | 0 (0) | 20 | 0 | 0 | English
CALL FOR ABSTRACTS Poster Session on Genomics and Proteomics
10TH Annual FDA Science Forum
FDA Science: The Critical Path from Concept to Consumer
May 18-19, 2004, Washington Convention Center
Co-sponsored by FDA, Williamsburg BioProcessing Foundation, Sigma Xi, AOAC and Prous Science http://www.dcscienceforum.org/
About the FDA Science Forum: T ... more>>
| | | |
| results / page 15/25/50 |
Page: 8 of 34
|
...8...34
|
|